Nature Communications (Nov 2017)
Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
- Pengju Wang,
- Xiaozhu Li,
- Jiwei Wang,
- Dongling Gao,
- Yuenan Li,
- Haoze Li,
- Yongchao Chu,
- Zhongxian Zhang,
- Hongtao Liu,
- Guozhong Jiang,
- Zhenguo Cheng,
- Shengdian Wang,
- Jianzeng Dong,
- Baisui Feng,
- Louisa S. Chard,
- Nicholas R. Lemoine,
- Yaohe Wang
Affiliations
- Pengju Wang
- Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University
- Xiaozhu Li
- CAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences
- Jiwei Wang
- Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University
- Dongling Gao
- Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University
- Yuenan Li
- Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University
- Haoze Li
- Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University
- Yongchao Chu
- Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University
- Zhongxian Zhang
- Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University
- Hongtao Liu
- Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University
- Guozhong Jiang
- Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University
- Zhenguo Cheng
- Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University
- Shengdian Wang
- CAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences
- Jianzeng Dong
- Department of Cardiology, The First Affiliated Hospital of Zhengzhou University
- Baisui Feng
- Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University
- Louisa S. Chard
- Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London
- Nicholas R. Lemoine
- Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University
- Yaohe Wang
- Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University
- DOI
- https://doi.org/10.1038/s41467-017-01385-8
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 15
Abstract
Interleukin-12 (IL-12) is a potent immunotherapeutic agent.
